Z John Zhong
Overview
Explore the profile of Z John Zhong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
3335
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Y, Lu B, Foster R, Zhang Y, Zhong Z, Chen M, et al.
J Biopharm Stat
. 2022 Jan;
32(1):124-140.
PMID: 35098880
Randomized clinical trials (RCTs) have often been considered as the gold standard in drug development, but they may not be fully powered due to limited patient population and can even...
2.
Finkel R, Mercuri E, Darras B, Connolly A, Kuntz N, Kirschner J, et al.
N Engl J Med
. 2017 Nov;
377(18):1723-1732.
PMID: 29091570
Background: Spinal muscular atrophy is an autosomal recessive neuromuscular disorder that is caused by an insufficient level of survival motor neuron (SMN) protein. Nusinersen is an antisense oligonucleotide drug that...
3.
Han B, Zhan J, Zhong Z, Liu D, Lindborg S
Pharm Stat
. 2017 Jun;
16(4):296-308.
PMID: 28560815
The borrowing of historical control data can be an efficient way to improve the treatment effect estimate of the current control group in a randomized clinical trial. When the historical...
4.
Cai W, Fiscella M, Chen C, Zhong Z, Freimuth W, Subich D
Clin Pharmacol Drug Dev
. 2016 Apr;
2(4):349-57.
PMID: 27121939
This Phase 1 study evaluated the absolute bioavailability, pharmacokinetics (PK), tolerability, and safety of belimumab 200 mg/mL administered subcutaneously (SC) to healthy subjects as a single dose and as multiple...
5.
Furie R, Petri M, Strand V, Gladman D, Zhong Z, Freimuth W
Lupus Sci Med
. 2014 Nov;
1(1):e000031.
PMID: 25396065
Objective: Correlates of systemic lupus erythematosus (SLE) Responder Index (SRI) response with clinical trial end points were examined using pooled data from the Study of Belimumab in Subjects with SLE...
6.
Petri M, van Vollenhoven R, Buyon J, Levy R, Navarra S, Cervera R, et al.
Arthritis Rheumatol
. 2014 Feb;
66(2):480.
PMID: 24504823
No abstract available.
7.
Ginzler E, Wallace D, Merrill J, Furie R, Stohl W, Chatham W, et al.
J Rheumatol
. 2013 Nov;
41(2):300-9.
PMID: 24187095
Objective: To evaluate the efficacy/safety of belimumab plus standard therapy in patients (n = 449) with active systemic lupus erythematosus (SLE) treated up to 7 years (n = 177 currently...
8.
Petri M, van Vollenhoven R, Buyon J, Levy R, Navarra S, Cervera R, et al.
Arthritis Rheum
. 2013 Jun;
65(8):2143-53.
PMID: 23754628
Objective: To identify predictors of moderate-to-severe systemic lupus erythematosus (SLE) flare in 562 patients treated with standard therapy alone in phase III belimumab trials, and to evaluate the impact of...
9.
Stohl W, Merrill J, McKay J, Lisse J, Zhong Z, Freimuth W, et al.
J Rheumatol
. 2013 Apr;
40(5):579-89.
PMID: 23547209
Objective: To evaluate the efficacy/safety of belimumab in patients with rheumatoid arthritis (RA). Methods: Patients fulfilling American College of Rheumatology (ACR) criteria for RA for ≥ 1 year who had...
10.
Strand V, Levy R, Cervera R, Petri M, Birch H, Freimuth W, et al.
Ann Rheum Dis
. 2013 Mar;
73(5):838-44.
PMID: 23524886
Objective: Assess the effects of belimumab treatment plus standard systemic lupus erythematosus (SLE) therapy on health-related quality of life (HRQOL) in patients with active, autoantibody-positive SLE. Methods: Patients received standard...